Ⅲ期非小细胞肺癌的综合治疗：围手术期化疗和免疫治疗的地位如何？
Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
机构信息
Hospital Universitario Puerta de Hierro, Majadahonda. Servicio de Oncología Médica, Madrid, Spain.
出版信息
Curr Opin Pulm Med. 2024 Jul 1;30(4):346-351. doi: 10.1097/MCP.0000000000001079. Epub 2024 May 7.
PURPOSE OF REVIEW
Early-stage nonsmall cell lung cancer (NSCLC) accounts for 30% of the total NSCLC, being the stage III a heterogeneous disease that represents a challenge in the management of these patients. Multidisciplinary approach is essential for an adequate treatment strategy, with surgery being the only curative treatment. Neoadjuvant or adjuvant chemotherapy has been the standard of care for a long period, with modest results.
RECENT FINDINGS
Combination of chemotherapy and immunotherapy has revolutionized the neoadjuvant setting of resectable NSCLC, improving pathologic complete responses and survival outcomes in this scenario. Furthermore, perioperative treatment with immunotherapy has also recently shown promising results in several phase III trials.
SUMMARY
The landscape of early-stage resectable NSCLC has evolved in recent years, with an improvement in the survival of these patients since the incorporation of immunotherapy in this scenario.
目的综述
早期非小细胞肺癌（NSCLC）占 NSCLC 的 30%，III 期 NSCLC 是一种异质性疾病，对这些患者的治疗提出了挑战。多学科方法对于制定适当的治疗策略至关重要，手术是唯一的治愈性治疗方法。新辅助或辅助化疗长期以来一直是标准治疗方法，但效果有限。
最新发现
化疗和免疫疗法的联合已彻底改变了可切除 NSCLC 的新辅助治疗，提高了该治疗场景下的病理完全缓解率和生存结局。此外，免疫治疗的围手术期治疗也在最近的几项 III 期试验中显示出了有前途的结果。
总结
近年来，早期可切除 NSCLC 的治疗格局发生了变化，由于免疫疗法在这种情况下的应用，这些患者的生存率得到了提高。
Zotero 插件